

## Epidemiological study of *Entamoeba histolytica* in cancer patients

Zubaida Najat Mustafa<sup>1</sup>, Abdul-Rahman A.Al-tae<sup>2</sup>, Abdulgani M. Al Samarai<sup>3</sup>

<sup>1</sup> Kirkuk University/ College of Science -Biology Department

<sup>2,3</sup> Tikrit University/ collage of Medicine- Microbiology Department

### Abstract

Amebiasis caused by *Entamoeba histolytica* is a third leading causes of death in worldwide. Little is known about its occurrence of parasite in subjects with cancer patients after receiving chemotherapy. This study aimed to determine, the frequency of *E. histolytica* in cancer patient admitted to oncology department in Kirkuk Teaching Hospital . Fresh stool specimens collected from 93 patients, detected by the *E. histolytica* / *E. dispar* olyclonal EILISA tests. Solid tumor form were the predominant type (65/93;69.8%)while the hematological cancer form were 30.1%(28/93, according to type of stool the high rate was demonstrate in semi –solid stool while according to color of stool was demonstrate in yellow colored stool. Cancer patients with *E. histolytica* / *E. dispar* were mostly from urban area then from rural area . *E. histolytica* / *E. dispar* positive cases occurred in patients whose their family were  $\geq 6$  individuals. And The high *E. histolytica* /*E. dispar* were demonstrated positive cases in illiterate individual

Keywords: *E. histolytica* , *E. dispar* ,Solid form tumor , Hematology form tumor

Residency & Educational state.

### Introduction

Amebiasis is responsible for approximately 100,000 deaths per year, mainly in Central and South America, Africa, and India, as well as for considerable morbidity manifested as invasive intestinal or extra-intestinal clinical features. Amebiasis infections are endemic in most temperate and tropical climates in the developing world. In some tropical countries, antibody prevalence rates (reflecting past or recent infection) exceed 50 %. The prevalence of Amebiasis varies with the population of individuals affected, differing between countries and between areas with different socioeconomic conditions[1]. Sometimes up to 50 % of the population is affected in regions with poor sanitary conditions. It is thought that Amebiasis directly affects over 50 million people, causing loss of

manpower and subsequent economic damage[2]. Transmission depends heavily on contaminated food and water, filth flies and cockroaches also are important mechanical vectors of cysts, their sticky, bristly appendages easily can carry cysts from a fresh stool to the dinner table, and the house fly habits of vomiting and defecating while feeding is an important mean of transmission. Carriers (cyst passers) handling food can infect the rest of their family or even other peoples if they work in restaurants, the uses of human feces as fertilizer in Asia, Europe and South America contribute to transmission. Reservoir host other than humans including dogs, pigs, and monkeys may play a role in the transmission of the disease[3].

Exposure to *E. histolytica* cysts can occur via Contaminated water and

## Epidemiological study of *Entamoeba histolytica* in cancer patient

food, spread by direct contact with an infected person's hands or with contaminated surfaces. Consuming food grown in feces-contaminated soil, fertilizer, or water. *E. histolytica* cysts can survive for weeks under moist conditions. Swimming pools are a possible source of contamination because *E. histolytica* survives chlorine levels sufficient to kill bacteria(3,4)

In up to 90% of *E. histolytica* infections, the symptoms are absent or very mild. These patients have normal rectosigmoidoscopic findings, without a history of blood in stool samples. Cysts and trophozoites lacking ingested RBCs may be visible on microscopy. Interestingly, most individuals infected with *E. histolytica*, but not *E. dispar*, develop serum antibody responses to the parasite even in the absence of invasive disease. So far, *E. dispar* has never been recognized as a cause of colitis or amebic liver abscess, although infection with these amebae is much more common than with *E. histolytica*, especially in developed countries(3). At the present, the diagnosis of intestinal amebiasis in many countries relies commonly on microscopic examination of stool samples for the presence or absence of *E. histolytica*/*E. dispar*. Unfortunately, it is not clear what percentage of patients infected with *E. histolytica* are asymptomatic. It was thought that asymptomatic infection by *E. histolytica* is common; signs and symptoms of invasive amebiasis develop in approximately 10% of the infected population. Estimation of the true prevalence of amebiasis is not easy, because many studies were done with just one microscopic examination of a stool sample. Asymptomatic *E. dispar* infections do not show evidence of disease or a serum anti-amebic antibody response, while symptomatic *E. histolytica* intestinal

infection does show a systemic immune response (5).

As with other enteric organisms, antigen-specific secretory immunoglobulin A (IgA) antibodies have been found to mediate protection against intestinal infection by *Entamoeba* species(6,7). Colonic mucins are rich in galactose-containing carbohydrates and have been demonstrated to be the high-affinity receptor for the *E. histolytica* galactose-inhibitable surface lectin. In general, intestinal IgA antibodies prevent microbial binding to epithelial surfaces and promote clearance of pathogenic enteric organisms by agglutination and blocking of surface receptors essential for microbial pathogenesis and invasion[8].

In addition, the duration of the human intestinal anti-lectin IgA antibody response has been reported to be as short as a mean of 17 days to as long as 36 months in 53% of amebic liver abscess (ALA) subjects. Numerous groups are working on a galactose-inhibitable lectin-based amebiasis subunit vaccine designed to induce a protective mucosal or cellular immune response[9]. Without further characterization of the human intestinal immune response and a better understanding of the dynamics (intensity and duration over time) of this response, it will be impossible to rationally develop and design a lectin-based amebiasis subunit vaccine for study in animal models and humans[10].

### **Materials and Methods**

A total of 93 stool samples were collected from patients complaining from malignant cancer with abdominal disorder (abdominal pain and diarrhea) were used in the present study. The samples were collected from patients with cancer during their attendance to Oncology Department at AL-Azadi Teaching Hospital from

period February 2013 to February 2014. Patients age were ranged from 1-10 to 81-90 years .

## 2.1 Sample collection:-

### 2.1.1.Stool collection:-

A fresh stool sample was collected from each patient using disposable plastic container .Then examined using double wet preparation as see with light microscopy using. Small amount (0.5 ml - 3 ml) of stool specimens were stored in sterile screw cap containers and kept at - 20°C using deep freez until being examined by ELISA.

Examination of stool specimens

Direct (Wet Mount) Examination

Stool samples were examined by wet mount preparation to detect the trophozoites and/or cysts of *E. histolytica* / *E. dispar*. Two slides were prepared for each sample, using a clean grease free slides, a small drop of normal saline was placed on the slide and mixed with a small pea size after well mixing of the sample using a wooden stick, a clean cover slid then placed and the specimen examined using light microscopy under low and high power magnification. The identification of the parasite was done by direct wet mount using normal saline 0.9 %, buffered methylene blue, and lugol's iodine 1 % (WHO, 1991)( 11 ).

### ELISA for *E. histolytica* / *E. dispar* Stool Antigen[11].

(Diagnostic Automation Co. Germany)

The Diagnostic Automation Inc. ELISA stool antigen assay was performed on 93 of stool samples from patients with cancer and 10 control stool specimens (microscopy negative for *E. histolytica* / *E. dispar* trophozoite and/or cyst) and the test performed according to manufacturing company.

## Results

A total of 93 patients with malignant cancer complaining from abdominal disorder (abdominal pain and diarrhea) were enrolled in the present study and healthy group 10 non infected with amebiasis and without cancer of different age groups nearly match to infected group of cancer patients. Table 1

According to the clinical investigation, and histopathological examination the patients divided into solid group of cancer which involved that of digestive system: (colon cancer, pancreatic cancer and gastric cancer) and hematology form cancer which included leukemia and lymphoma. Solid tumor form the predominant type (65/93; 69.8%) while the hematological cancer form 30.1% (28/93), of the solid tumor, colon cancer was the common (29/65:44%) followed by gastric cancer (21/65:32.3%) and pancreatic cancer (15/93:23%). While in the hematological cancer form leukemia was (15/28: 53.57%) and lymphoma was (13/28: 46.42%).Table2

The higher rate of *E. histolytica* /*E. dispar* was demonstrate in semi -solid stool (45.98%,17/37), followed by solid stool( 30.4%, 7/23) and then liquid stool (27.27%, 9/33). However, the differences were not statistically significant ( $X^2=2.993$ ,  $P>0.05$ ), Table 3.

The higher rate of *E.histolytica* / *E.dispar* positivty was demonstrated in yellow colored (64.2%) stool, while the lowest was in black colored stool (0%), with significant difference ( $X^2 = 14.252$  ;  $P= 0.003$ ), Table 3.

Regarding residency, Table 4 shows that 48 (51.6%) cancer patients were from urban area while 45(48.4%) cancer patients were from rural area. Thus there was no significant difference in distribution of cases between rural and

## Epidemiological study of *Entamoeba histolytica* in cancer patient

urban areas ( $X^2 = P > 0.05$ ). The infection rate with *E. histolytica* in urban areas was 23 (24.73%), while in rural area was 10 (10.75%), with significant difference ( $X^2 = 6.698$  and  $P = 0.01$ ).

Table 5) shows that 66.7% (22/33 cases) of *E. histolytica* / *E. dispar* positive cases occurred in patients whose family were  $\geq 6$  individuals. In addition, large size families ( $\geq 6$  individual) accounted for 23.65%. *E. histolytica* infection from the total cases (22/93 cases). However, there was non significant ( $X^2 = 2.381$ ,  $P > 0.05$ ) differences in positivity rate in relation to family size.

The high *E. histolytica* / *E. dispar* were demonstrated positive cases in illiterate individual (33.3%), followed by primary school educational level (30.3%:10/33) and secondary school level (24.2, 8/33 cases). While the lowest rate of infection with *E. histolytica* / *E. dispar* was lower (6.1, 2/33) in the subject with higher educational level, (Table 6).

When the comparison preformed between those with educational level of secondary and below and those with higher educational level the rate of infection with *E. histolytica* was 38.2 (29/76 cases) in secondary education and below, while it was 3.5% in those with higher educational level, (Table 7).

### Discussion

The present study indicated that *E. histolytica* / *E. dispar* infection was detected in 35.5% of cancer patients with developed infection with *E. histolytica* / *E. dispar*.

In literature, the prevalence of *E. histolytica* infection varies globally [12], and with a range of 1% in developed countries and 80% in developing countries [13]. In Iraq, the reported studies suggest a incidence rate of 20.7% to 29.5%. But in a restudy preformed in

Basrahm suggest a incidence of 27.7% in adult [14].

This the higher prevalence rate of *E. histolytica* / *E. dispar* in our subject patients could be attributed to immunosuppressive state in patients with cancer. Subjects with some type of immunocompromised status and those receiving immunosuppressive chemotherapy have an increased incidence of parasitic infection including *E. histolytica* [15-18].

The present study *E. histolytica* incidence rate was higher to that reported by Botero et al. [19], as they found incidence rate of 9.91% in immunocompromised patients. However, the above incidence rates were including *E. histolytica* / *E. dispar*, but in this study *Ent. histolytica* incidence rate was 10.7% and thus *E. dispar* forms 24.8% which was non pathogenic. However the comparison is difficult since different studies were with different study designs.

Cancer type influenced the infection with *E. histolytica* / *E. dispar* as this study indicated. Patients with solid cancer show a rate of infection with *E. histolytica* / *E. dispar* as compared to hematogenous cancer. In addition, within the solid tumor the infection rate with *E. histolytica* / *E. dispar* was higher in patients with colonic and pancreatic cancer than in those with gastric cancer. However, the difference was not significant. Furthermore, *E. histolytica* / *E. dispar* infection was significantly higher in patients with leukemia as compared to those with lymphoma.

A study preformed in Saudia Arabia [20], reported incidence rate of 5.2% for *E. histolytica* in immunocompromised patients. In addition, Mohanad et al. [21] reported a rate of 1.7% for *E. histolytica* in Northern India. However, the present study *E. histolytica* infection rate was relatively higher than that previously reported for western Nepal

## Epidemiological study of *Entamoeba histolytica* in cancer patient

(27.7%)[22], Colombia (25.2%) Florez et al.[23], Ethiopia (24.8%)[24].

In a recently reported study, *E. histolytica* infection was reported in 5.7% among HIV/AIDS patients in Nigeria. However *E. histolytica* /*E. dispar* infection rate in HIV/AIDS patients was influenced by sexual behavior[25]. Furthermore, in a pediatric immunocompromised population, the infection rate was 4.7% [26].

Although infected host with *E. histolytica* deploys a strong immune response, the parasite has developed a remarkable number of mechanisms to evade these attacks[27]. The diversity in *E. histolytica* infection rate in immunocompromised individual as this study indicated and as reported in literature are due to different factors.

The factors that influence variation in infection rate with *E. histolytica* in immunocompromised subjects include personal difference in innate immunity, ability of parasite strains to evade host immune response, variability of host inflammatory response that contribute to tissue damage, and host genetics[28, 29]. Parasitic infection severity, natural course and manifestation was modified by the compromise in host immune response[30].

Cancer was associated with immune deficiency and this subsequently enhances the emergence of infection. Since the suppression is not presented as entity, thus there is a differences in infection rates with *E. histolytica* in different reported studies settings[31].

A recently reported study[32], suggest that in animal model, the presence of commensal Clostridia- related bacteria in gut is protective during *E. histolytica* infection. This finding may add explanation for host response differences to *E. histolytica* infection and geographical variation in infection rate in

immunocompetent and immunocompromised subjects.

Amoebiasis or unknown factors related to infection with *E. histolytica* may stimulate the proliferation of Lymphoma cells[33]. Although present study finding indicated that tumor type may influence *E. histolytica* infection rate, other study[33], not reported a statistical significant differences between the different type of immunocompromised condition. In previous studies on adults immunocompromised population who are with cancer, the prevalence rate varied from 2%to 50% for parasitic infection[34]. About similar prevalence rates (42%) were demonstrated in immunocompromised children with malignant disease [35].

Parasitic infections also reported in 84.3%of subjects with HIV infection. The present study incidence rate was lower to that reported for Indonesia in immunocompromised children[36] and Malaysia[37].

The present study indicated that *E. histolytica* infection was more predominant (45.9%) in semi-solid stool type. However, *E. histolytica* infection rate differences between stool types were statistically not significant. This finding not agreed to that reported by others in immunocompetent children and adults as they reported high infection rate in liquid stool[38-40]. This variation may be explained on the basis of that immune deficiency/suppression lead to change in the ecology of microbial flora of the gut. Such changes may influence the presence or absence of certain microbes including parasites such as *E. histolytica* /*E. dispar*. *E. histolytica* infection rate differ significantly between different stool color and the rate of infection was predominant in yellow colored stool.

Residence not influence the distribution of cancer cases, however, *E. histolytica* / *E. dispar* infection rate was

## Epidemiological study of *Entamoeba histolytica* in cancer patient

significantly higher in urban than in rural areas ( $X^2 = 6.698$ ,  $P = 0.01$ ). This finding agreed to that reported recently [40], in immunocompetent subjects in Kirkuk and to that reported by Kurt et al [41]. However, the present study finding is not consistent to that reported for Samara as there is no difference in prevalence between rural and urban areas [42]. In addition, this study findings disagree with finding of Kadir and Saloman study in Al-Tameem province [43], that showed a high infection rate in rural than in urban areas. Moreover, the study differ from AL-Samarray [38], who recorded a higher infection rate in rural than in urban.

The higher infection rate in urban than in rural may be due to increasing density of immigrants in Kirkuk city especially after the occupation of Iraq by the coalition forces in 2003. In addition, personal hygiene and low socioeconomic status in urban areas and may affect the infection rate in urban area.

Family individual of  $\leq 6$  was with higher infection (66.7%) rate as compared to other family size. However, the difference was not statistically significant. This finding was consistent to that reported recently (48.05%) for Kirkuk in normal individuals [40]. In addition, other studies reported a higher incidence of infection in large size as compared to small size families [44,45].

The present study indicated a decreased in *E. histolytica* infection rate with increase in education level. However, the differences not reach a significant level. This finding was agreed to that reported recently for Kirkuk [40], in immunocompetent subjects and that reported in other geographical areas [46].

### References

Tanyuksel M, Petri W A. Laboratory diagnosis of amebiasis. Clin Microbiol. Rev 2003; 16:713-729.

Geraled D S, Larry S R. Foundations of Parasitology. MacGraw-Hill Companies. New York 2005; 7th Ed. PP: 107-114.

Lebbad M. Molecular Diagnosis and Characterization of Two Intestinal Protozoa: *Entamoeba histolytica* and *Giardia intestinalis* [PhD thesis]. Stockholm. Karolinska Institutet; 2010.

Stauffer W, Ravdin J I. 2003. *Entamoeba histolytica*: An update. Curr Opin Infect Dis 2003; 16:479-485.

Garcia, L. S., and D. A. Bruckner. Diagnostic medical parasitology, 3rd ed. ASM Press, Washington, D.C; 1997.

Rivera W L, Santos H J, Ong V A, Murao L J. Profiles of *Entamoeba histolytica*-specific immunoglobulins in human sera. Asian Pacific J of Trop Med 2012; 234-238.

Ravdin J I, Abd-Alla M, Welles S, Reddy S, Jackson T G. Intestinal antilectin immunoglobulin A antibody response and immunity to *Entamoeba dispar* infection following cure of amebic liver abscess. Infect Immun 2003; 71:6899-6905

Abd-Alla M D. Mucosal immune response to parasitic infections, p. 815-829. Mestecky (ed.), Mucosal immunology, 3rd ed. Elsevier Academic Press, Amsterdam, The Netherlands; 2005

Abd-Alla M D, Jackson T F, Rogers T, Reddy S, J I. Mucosal Immunity to Asymptomatic *Entamoeba histolytica* and *Entamoeba dispar* Infection Is Associated with a Peak Intestinal Anti-Lectin Immunoglobulin A Antibody Response. Infect Immun 2006; 74 (7): 3897-3903.

WHO. Basic Laboratory Methods in Medical Parasitology. 1st Ed. Printed in England. Macmillan/ Clays; 1991.

Diagnostic Automation, Inc., USA. *E. histolytica*/*E. dispar* ELISA Kit; cat: 8307-3.

World Health Organization (2007) WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-

## Epidemiological study of *Entamoeba histolytica* in cancer patient

related disease in adults and children. Geneva.

Stacey L. Burgess S. L., Buonomo E., Carey M., Cowardin C., Naylor C, Zannatun N, Marsha W. William A. P and Jr. P. Caitlin Bone Marrow Dendritic Cells from Mice with an Altered Microbiota Provide Interleukin 17A-Dependent Protection against *Entamoeba histolytica* Colitis. *mBio* 5(6):e01817-14. doi:10.1128/mBio.01817-14.

Al-Shaheen .Z, AL-Makia A.,K and Hyssein K., K. A Study On Prevalence Of *Entameba histolytica* & *Giardia lamblia* Infection Among Patient Attending Qurna Hospital In Basrah.2007.Bas. J.Resw.Vol.6.NO.2

Corredor, A., Drydn, M.S., Shanon,D.C., &Gazzard,B. G., Cryptosporidial diarrhea in AIDES Gut,29:539-597,1988.

Mannheimer SB. & Sova R. Protozoal infection in patients with AIDS. Cryptosporidiosis, isosporiasis, cyclosporiasis and microsporidiosis. *Infect. Dis. Clin. North Amr.*, 483-498.1694

Rotterdam,H& Tsang,P.Gastrointestinal disease in the immunocompromised patients. *HUM. Path.*,25:1123-1140,1994

Smith, P.D., Lanem H., C. Gill,V.,J. .Intestinal infection in the patients with the acquired immunodeficiency syndrome (AIDS). Etiology and response to therapy. *Ann. Intern. Med.*, 108 : 328-333.1995.

Botero JH., Casano A, Montoya MN., Ocampo NE, Hurtadomi A. and Loperaam M. Preliminary study of the prevalence of intestinites al parasites in immunocompromised patients with and without gastrointestinal manifestations. *Inst. Med. trop. S. Paulo* 45(4):197-200, July-August, 2003.

Al-Megrin WA. Intestinal parasites infection among immune- ocompromised patients in Riyadh, Saudi Arabia. *Pak J Biol Sci.* 15;13(8):390-4, 2012.

Muhanad. K, Sehgal. R.A and Sud, N. M. Prevalence of intestinal parasitic pathogens in HIV-seropositive individuals in Northern India. *Jpn J Infect Dis*,55:83-4, 2002.

Shrestha A, Narayan KC and Sharma R. Prevalence of intestinal parasitosis among school children in Baglung districts of Western Nepal. *Kathmandu Univ Med J (KUMJ)*. 2012 Jan-Mar;10(37):3-6

Florez AC, Garcia DA, Moncada L, Beltran M . Prevalence of Microsporidia and other intestinal parasites in patients with HIV infection, Bogota, 2003. *Biomedica* 23(3):274-82

Assefa S., Erko B., Medhin G., Assefa Z.and Shimelis T. Intestinal parasitic infections in relation to HIV/AIDS status, diarrhea and CD4 T-cell count. *BMC Infect. Dis.*, 9: 155-155, 2009.

Lowther A., Dworkin MS. And Hanson DL. The Adult and Adolescent Spectrum of Human Immunodeficiency Virus Disease Project *Entamoeba histolytica/Entamoeba dispar* in human immunodeficiency virus-infected patients in the United States. *Clin Infect Dis* 30: 955–959, 2000

Idris NS., wipoerwantoro D., Kurniawan PG and Said AM. Intestinal parasitic infection of immunocompromised children with diarrhoea: clinical profile and therapeutic response. *The Journal of Infection in Developing Countries.* 2010. 4(5), 309-17.

Moonah Sh N, Wiliam NM., Jiangm AM and Jr WA. Host Immune Response to Intestinal Amebiasis. *Plos Published*: 2013. DOI: 10.1371/journal.ppat.1003489, 2013.

## Epidemiological study of *Entamoeba histolytica* in cancer patient

- Bansal D, Ave P, Kerneis S, Frileux P and Boche' O. An ex-vivo human intestinal model to study *Entamoeba histolytica* pathogenesis. *PLoS Negl Trop Dis*. 2009.3: e551. doi:10.1371/journal.pntd.0000551]
- Yu Y., Chadee K. *Entamoeba histolytica* stimulates interleukin 8 from human colonic epithelial cells without parasite-enterocyte contact. *Gastroenterology* .2000.112: 1536–1547. doi: 0.1016/s0016-5085(97)70035-0.
- Evering T and Weiss LM. The immunology of parasite infections in immunocompromised hosts. *NIH Puolic Acess.Parasite immunol*.2006.28 (11):549-565. Doi:10.1111/j.1365-3024.2006.00886
- Samie A, Obi L C, Bessong P O, et al. Prevalence and species distribution of *Entamoeba histolytica* and *Entamoeba dispar* in the Venda region, Limpopo, South Africa. *Am J Trop Hyg* 2006; 75 (3): 565-571 2006.
- Burgess S, Buonomo E, Carey M, Cowardin C, Naylor C, Noor Z, M. Wills-Karp A P. and William J. Bone Marrow Dendritic Cells from Mice with an Altered Microbiota Provide Interleukin 17A-Dependent Protection against *Entamoeba histolytica* Colitis.2014. Volume 5 Issue 6 e01817-14.
- Botero JH., Casano A, Montoya MN., Ocampo NE, Hurtadomi A. and Loperaam M. Preliminary study of the prevalence of intestinites al parasites in immunocompromised patients with and without gastrointestinal manifestations. *Inst. Med. trop. S. Paulo* 45(4):197-200, July-August, 2003.
- El-difrawy M, Nanaa H, Eissa M, Sadaka H, Nomir A Study of parasitic infections in immunocompromised patients in Haematology Department at Main University Hospital, Alexandria. *Exp Pathol Parasitology*.2002. 10: 85-92
- Menon BS, Abdullah MS, Mahamud F, Singh B. Brief report. Intestinal parasites in Malaysian children with cancer. *J Trop Pediatr*.1999. 45: 241-242.
- Menon BS, Abdullah MS, Mahamud F, Singh B. Brief report. Intestinal parasites in Malaysian children with cancer. *J Trop Pediatr*.1999. 45: 241-242.
- Redondo R B, Mendez L G., Bear G. *Entamoeba histolytica* and *Entamoeba dispar*: Differentiation by Enzyme-Linked Immunosorbent Assay (ELISA) and its clinical correlation in pediatric patients. *Parasitol Latinoam* 2006; 61: 37-42
- AL-Samarray S A H. Epidemiological and biological study of *Entamoeba histolytica* in Salahaddin governorate/ Samarra. [M. Sc. Thesis]. College of Science, Tikrit University; 2008.
- Hooshyar H, Rezaian M, Kazemi B, Jeddi-Tehrani M, Solaymani-Mohammadi S. The distribution of *Entamoeba histolytica* and *Entamoeba dispar* in northern, central, and southern Iran. *Parasitol Res* 2004; 94: 96–100.
- Mahmood A. A. Isolation and Differentiation between *Entameba histolytica* and *Entameba dispar* Using ELISA and Real Time-PCR Techniques[M. Sc. Thesis]. College of Medicine, Tikrit University; 2013.
- Kurt O, Demirel M, Ostan I, et al.. Investigation of the prevalence of amoebiasis in Izmir province and determination of *Entamoeba* species using PCR and enzyme immunoassay. *New Microbiol* 2008; 31: 393-400
- Kadir M A, Al-Nooman N, Al-Samarie H M. A study of protozoal diarrhea in Samarra district. *J Fac Med Baghdad* 2000; 42(4): 678–686.
- Kadir M A,Salman Y G. Prevalence of intestinal parasites among primary school children in different localities in Al-

## Epidemiological study of *Entamoeba histolytica* in cancer patient

Tameem province accepted to published in Ann coll Med. Mosul 1990.

Ismail A M. Diagnostic study of *Entamoeba histolytica*/ *Entamoeba dispar* and its relation with pathogenic bacteria causing diarrhea in children[Ph. D. Thesis ] College of Medicine, Tikrit University; 2006

AL-Bayati Z., M. Study on Prevalence of *Entamoeba histolytica* and *Entamoeba*

*dispar* in Kirkuk city usig Enzyme Linked Immunosorbent Assay.[M. Sc. Thesis]. College of Science, Tikrit University; 2003.

Morales-Espinoza E M, Sanchez-Perez H J, Garcia-Gil M M, et al. Intestinal parasites in children, in highly deprived areas in the border region of Chiapas, Mexico. Salud Publica Mex 2003; 45(5): 379-388.

# Epidemiological study of Entamoeba histolytica in cancer patient

Table 1: Study population

| Group                                           |                        | Number |
|-------------------------------------------------|------------------------|--------|
| Infected(Cancer patient with amebiasis)         | Detected with Tak labI | 33     |
| Non –infected cancer patient without amebiasis. |                        | 66     |
| Control group                                   |                        | 10     |

Table 2:- Frequency distribution of cancer type in study population.

| Type of cancer       |                   | No. of patients | %     |
|----------------------|-------------------|-----------------|-------|
| Solid cancer         | Colon cancer      | 29              | 31.1% |
|                      | Gastric cancer    | 21              | 22.6% |
|                      | Pancreatic cancer | 15              | 16.1% |
|                      | Total             | 65              | 69.9% |
| Hematological cancer | Leukemia          | 15              | 16.1% |
|                      | Lymphoma          | 13              | 14%   |
|                      | Total             | 28              | 30.1% |
| Total                |                   | 93              |       |

Table 3: Macroscopic examination of stool specimens from cancer patients

| Characteristics |                   | Tested cases.<br>(93) |        | E. histolytica / E.dispar |        |          |        |
|-----------------|-------------------|-----------------------|--------|---------------------------|--------|----------|--------|
|                 |                   |                       |        | Positive                  |        | Negative |        |
|                 |                   | No.                   | %      | No.                       | %      | No.      | No.    |
| Consistency     | Liquid (diarrhea) | 33                    | 35.4%  | 9                         | 27.27% | 24       | 72.72% |
|                 | Semi-solid        | 37                    | 39.78% | 17                        | 45.9%  | 20       | 54.05% |
|                 | Solid             | 23                    | 24.73% | 7                         | 30.4%  | 16       | 69.56% |
|                 |                   | X2 = 2.993            |        | P= 0.223                  |        |          |        |
| Color           | Yellow            | 14                    | 15.05% | 9                         | 64.2%  | 5        | 35.71% |
|                 | Greenish          | 31                    | 33.33% | 15                        | 4.38%  | 16       | 51.61% |
|                 | Dark brown        | 42                    | 45.1%  | 9                         | 21.4%  | 33       | 87.57% |
|                 | Black             | 6                     | 6.45%2 | 0                         | 0      | 6        | 100%   |
|                 |                   | X2 = 14.251           |        | P=0.003                   |        |          |        |

# Epidemiological study of Entamoeba histolytica in cancer patient

Table 4: Frequency of E. histolytica / E. dispar according to residency

| Site of residency | No. Examined | No. Positive | Positive % | Positive % from total |
|-------------------|--------------|--------------|------------|-----------------------|
| Urban             | 48(51.6%)    | 23           | 51.11%     | 24.73% %              |
| Rural             | 45(48.4%)    | 10           | 22.22%     | 10.7% %               |
| Total             | 93(100%)     | 33           | 35.5%      | 25.66 %               |

$X^2 = 6.698$

$P = 0.010$

Table 5:- Frequency of E. histolytica / E. dispar according to family size.

| Family size | No. Examined | No. Positive | Positive from positive | % total | Positive % Per group | Positive % from total |
|-------------|--------------|--------------|------------------------|---------|----------------------|-----------------------|
| ≤3          | 13           | 3            | 9.1                    |         | 23.07%               | 3.22%                 |
| 4-5         | 16           | 8            | 24.2                   |         | 50%                  | 8.6%                  |
| 6≥          | 64           | 22           | 66.7                   |         | 34.375%              | 23.65%                |
| Total       | 93           | 33           | 100                    |         |                      | 35.48%                |

$X^2 = 2.381$

$p > 0.05$

Table 6:- Distribution of E. histolytica according education.

| Educational State        | No. of Examined | No. of positive | Positive % |
|--------------------------|-----------------|-----------------|------------|
| Illiterate               | 25              | 11              | 33.3%      |
| Primary                  | 35              | 10              | 30.3%      |
| Secondary                | 16              | 8               | 24.2%      |
| Preparatory              | 6               | 2               | 6.1%       |
| Institution and Bachelor | 11              | 2               | 6.1%       |
| Total                    | 93              | 33              |            |
| $X^2 = 4.446$            |                 | $P = 0.349$     |            |

Table 7:- Comparison of E. histolytica positivity rate between subjects with ≤ secondary and higher educational level.

| Educational level | Total | Positive   | %     |
|-------------------|-------|------------|-------|
| ≤ Secondary       | 76    | 29         | 38.2% |
| Higher            | 17    | 4          | 23.5% |
| $X^2 = 1.3$       |       | $P > 0.05$ |       |